3-aminopyrrolidine derivatives as modulators of chemokine...

Details 3-aminopyrrolidine derivatives as modulators of chemokine... 3-aminopyrrolidine derivatives as modulators of chemokine...

2003-11-26

2010-11-16

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S242000

Reexamination Certificate

active

07834021

ABSTRACT:
The present invention relates to 3-aminopyrrolidine derivatives of the formula I:(wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

REFERENCES:
patent: 4353734 (1982-10-01), Seres et al.
patent: 4785119 (1988-11-01), Hojo et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 6313117 (2001-11-01), Bekkali et al.
patent: 6326372 (2001-12-01), Evans et al.
patent: 6362177 (2002-03-01), Shiota et al.
patent: 6410566 (2002-06-01), Shiota et al.
patent: 6451842 (2002-09-01), Shiota et al.
patent: 7307086 (2007-12-01), Xue et al.
patent: 2002/0094989 (2002-07-01), Hale et al.
patent: 2005/0192302 (2005-09-01), Xue et al.
patent: 2005/0261310 (2005-11-01), Xue et al.
patent: 2006/0004018 (2006-01-01), Xue et al.
patent: 2006/0020133 (2006-01-01), Xue et al.
patent: 2006/0111404 (2006-05-01), Xue et al.
patent: 2007/0149532 (2007-06-01), Xue
patent: 10-298180 (1998-11-01), None
patent: 2004-83511 (2004-03-01), None
patent: 95/08533 (1995-03-01), None
patent: WO 97/44329 (1997-11-01), None
patent: WO 98/57641 (1998-12-01), None
patent: WO 99/25686 (1999-05-01), None
patent: 00/26186 (2000-05-01), None
patent: WO 00/59502 (2000-10-01), None
patent: WO 00/69432 (2000-11-01), None
patent: WO 00/69815 (2000-11-01), None
patent: WO 01/10439 (2001-02-01), None
patent: WO 01/19816 (2001-03-01), None
patent: WO 01/28987 (2001-04-01), None
patent: WO 02/034716 (2002-05-01), None
patent: WO 02/076945 (2002-10-01), None
patent: WO 03/092586 (2003-11-01), None
patent: WO 03/093231 (2003-11-01), None
patent: WO 03/093266 (2003-11-01), None
patent: WO 2004/020584 (2004-03-01), None
patent: 2004/026836 (2004-04-01), None
patent: WO 2004/041161 (2004-05-01), None
patent: WO 2004/041163 (2004-05-01), None
patent: WO 2004/041279 (2004-05-01), None
patent: WO 2004/041777 (2004-05-01), None
patent: WO 2004/042351 (2004-05-01), None
patent: WO 2004/050024 (2004-06-01), None
patent: WO 2005/044264 (2005-05-01), None
patent: WO 2005/044795 (2005-05-01), None
patent: WO 2005/067502 (2005-07-01), None
patent: WO 2005/070133 (2005-08-01), None
patent: WO 2005/072361 (2005-08-01), None
patent: WO 2006/073592 (2006-07-01), None
Helsley et al., J. Med. Chem (1968), vol. 11, p. 1034-1037.
Tak, P.P., “Chemokine inhibition in inflammatory arthritis”, Best Practice & Research Clinical Rheumatology, vol. 20, No. 5, 929- 939, 2006.
Reape et al., “Chemokines and atherosclerosis”, Atherosclerosis, 147, 1999, 213-225.
Yang et al., “Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists”, Bioorganic&Medicinal Chemistry Letters, 16, 2006, 3735-3739.
Butora et al., “3-amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2”, Bioorganic&Medicinal Chemistry Letters, 2007, doi:10.1016/j.bmcl.2007.04.053.
http://en.wikipedia.org/wiki/Prodrug (**1 Page Only**).
Han et al., “Targeted Prodrug Design to Optimize Drug Delivery”, AAPS PharmSci, 2000, 2(1), article 6. DOI 10.1208/ps020106 (**17 Pages**).
http://en/wikipedia.org/wiki/Levodopa (**4 Pages**).
Chawla et al., “Challenges in Polymorphism of Pharmaceuticals”, Crips vol. 5, No1, Jan.-Mar. 2004 (**4 Pages**).
Newman et al., “Solid-state analysis of the active pharmaceutical ingredient in drug products”, DDT vol. 8, No. 19, Oct. 2003, p. 898-905.
Moalem et al., “Immune and inflammatory mechanisms in neuropathic pain”, Brain Research Reviews 51 (2006), 240-264.
Treatment options for neuropathic pain, http://www.spine-health.com/topics/conserv
europaintr
europaintr01.html (**1 Page**).
Simon et al., “HIV/AIDS epidemiology, pathogenesis, prevention, and treatment”, www.thelancet.com, vol. 368, Aug. 5, 2006, p. 489-504.
Perez, “Current and future trends in the appication of HPLC-MS to metabolite0identification studies”, Drug Discovery Today, vol. 12, No. 5/6, Mar. 2007, p. 249-256.
Sundberg, “Implication of polymorphic cygochrome p450-dependent drug metabolism for drug development”, Drug Metabolism and Disposition, vol. 29, No. 4, part 2, p. 570-573.
Define:Disease treatment-Google Search (**1 Page**).
MedlinePlus Medical Encyclopedia: Metabolite (**1 Page**).
Pyelonephritis, Glomerulonephritis, Interstitial & Lupus Nephritis Symptoms (8 pages), http:/
ativeremedies.com/ailment
ephritis-kidney-inflammation-info.html.
IGA Nephropathy (5 pages), http://kidney.niddk.nih.gov/kudiseases/pubs/iganephropathy/.
Membranoproliferative Glomerulonephritis (4 pages), http://www.clinicaltrials.gov/ct2/show/NCT00275613?term=glomerulonephritis&rank=8.
Treatment of Primary Glomerulonephritis (2 pages), http://content.nejm.org/cgi/content/full/337/17/1250.
Incyte CCR2 Antagonist Program (13 pages).
Hot Targets—CCR2 in Inflammatory Disease (7 pages), http://www.pharmaweek.com/Exclusive—Content/1—19.asp.
MS Pipeline, http://mspipeline.wordpress.com/ (2009).
http://en.wikipedia.org/wiki/Prodrug (2007).
http://en/wikipedia.org/wiki/Levodopa (2007).
Treatment options for neuropathic pain, http://www.spine-health.com/topics/conserv
europaintr
europaintr01.html (2006).
Sundberg, “Implication of polymorphic cygochrome p450-dependent drug metabolism for drug development”, Drug Metabolism and Disposition, vol. 29, No. 4, part 2, p. 570-573 (2005).
define:Disease treatment-Google Search (2007).
MedlinePlus Medical Encyclopedia: Metabolite (2007).
Pyelonephritis, Glomerulonephritis, Interstitial & Lupus Nephritis Symptoms (2008), http:/
ativeremedies.com/ailment
ephritis-kidney-inflammation-info.html.
IGA Nephropathy (2008), http://kidney.niddk.nih.gov/kudiseases/pubs/iganephropathy/.
Membranoproliferative Glomerulonephritis (2006), http://www.clinicaltrials.gov/ct2/show/NCT00275613?term=glomerulonephritis&rank=8.
Treatment of Primary Glomerulonephritis (2008), http://content.nejm.org/cgi/content/full/337/17/1250.
Incyte CCR2 Antagonist Program (2006).
Hot Targets—CCR2 in Inflammatory Disease (2008), http://www.pharmaweek.com/Exclusive—Content/1—19.asp.
Database CASPLUS on STN (Columbus, OH) No. 136:200479, Kitajima et al., “Preparation of Proline Derivatives as Dipeptidyl Peptidase IV Inhibitors and use thereof as Drugs,” (2002).
Database CASPLUS on STN (Columbus, OH) No. 141:295848, Goodfellow et at, “Preparation of bis(3-aminopyrrolidin-1-yl)methanones as melanin-concentrating hormone receptor antagonists for treatment of obesity and other disorders,” (2004).
Greene,Protective Groups in Organic Synthesis, Ch. 7 “Protection for the Amino Group,” pp. 218-219, p. 232, and p. 236 (1982) Wiley-Interscience.
Bundgaard, “Design of prodrugs',” p. 27 and p. 33 (1986).
Van Vliet, Wikstrom, Pugsley, Heffner and Wise, Derivatives of Nemonapride (YM-09151-2) . . . Chapter 6, pp. 139-149.
Weisberg, S. P. et al., “CCR2 modulates inflammatory and metabolic effects of high-fat feeding.”J. Clin. Invest. (2006) 116(1), pp. 115-124; Epub 2005, Dec 8.
Non-Final Office action mailed Oct. 31, 2007 in connection with U.S. Appl. No. 11/014,322.
Response to Office Action dated Dec. 6, 2007 in connection with U.S. Appl. No. 11/014,322.
Final Office Action mailed Aug. 19, 2008 in connection with U.S. Appl. No. 11/014,322.
Non-Final Office action mailed May 17, 2007 in connection with U.S. Appl. No. 11/167,329.
Response to Office Action dated Aug. 16, 2007 in connect

Affiliated with

Also associated with

Rating

3-aminopyrrolidine derivatives as modulators of chemokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-aminopyrrolidine derivatives as modulators of chemokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-aminopyrrolidine derivatives as modulators of chemokine... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4227110